These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 26826402)

  • 21. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
    Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
    Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.
    Liu W; Shia J; Gönen M; Lowery MA; O'Reilly EM; Klimstra DS
    Pancreas; 2014 Nov; 43(8):1264-70. PubMed ID: 25058881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome.
    Plocharczyk EF; Frankel WL; Hampel H; Peters SB
    Am J Dermatopathol; 2013 Apr; 35(2):191-5. PubMed ID: 22722469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunohistochemical examination of MSH2, PMS2, MLH1, MSH6 compared with the analysis of microsatellite instability in colon adenocarcinoma].
    Raskin GA; Ianus GA; Kornilov AV; Orlova RV; Petrov SV; Protasova AÉ; Pozharisskiĭ KM; Imianitov EN
    Vopr Onkol; 2014; 60(2):47-50. PubMed ID: 24919261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Microsatellite instability of bilateral breast carcinomas is not linked to down-regulated expression of DNA mismatch repair genes].
    Kuligina ESh; Morreau N; Imianitov EN
    Vopr Onkol; 2010; 56(2):152-5. PubMed ID: 20552889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
    Cohen PR; Kurzrock R
    Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
    Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
    JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
    Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
    Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
    Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
    Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
    Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
    Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.
    Mojtahed A; Schrijver I; Ford JM; Longacre TA; Pai RK
    Mod Pathol; 2011 Jul; 24(7):1004-14. PubMed ID: 21499234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
    Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
    Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer.
    South CD; Yearsley M; Martin E; Arnold M; Frankel W; Hampel H
    Genet Med; 2009 Nov; 11(11):812-7. PubMed ID: 19752738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting.
    Overbeek LI; Ligtenberg MJ; Willems RW; Hermens RP; Blokx WA; Dubois SV; van der Linden H; Meijer JW; Mlynek-Kersjes ML; Hoogerbrugge N; Hebeda KM; van Krieken JH
    Am J Surg Pathol; 2008 Aug; 32(8):1246-51. PubMed ID: 18677806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act".
    Sheridan TB; Fenton H; Lewin MR; Burkart AL; Iacobuzio-Donahue CA; Frankel WL; Montgomery E
    Am J Clin Pathol; 2006 Oct; 126(4):564-71. PubMed ID: 16938659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.